Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study (Annals of Hematology, (2012), 91, 5, (679-685), 10.1007/s00277-011-1359-0);Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study

Annals of Hematology

Volumn 91, Issue 5, 2012, Pages 679-685

  Jönsson, Sofia ^a   Olsson, Bob ^a   Söderberg, Jenny ^b   Wadenvik, Hans ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Health Solutions AB   (Sweden)

Author keywords

Adherence; Chronic myeloid leukemia; Imatinib; Morisky score; Nine item MMAS; Treatment Response

Indexed keywords

BCR ABL PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BCR ABL GENE; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; DAILY LIFE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; POINT MUTATION; POPULATION RESEARCH; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TREATMENT RESPONSE; FOLLOW UP; GENETICS; MIDDLE AGED; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84861441763     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-017-3024-8     Document Type: Erratum

References (26)

1. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA (2009) Six-year followup of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054-1061
2. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035
3. Tilson HH (2004) Adherence or compliance? Changes in terminology. Ann Pharmacother 38:161-162 (Pubitemid 38018025)
4. World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva
5. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de LH, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381-2388
6. Noens L, van LierdeMA, De BR, Verhoef G, Zachee P, Berneman Z, Martiat P, Mineur P, Van EK, MacDonald K, De GS, Albrecht T, Abraham I (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401-5411
7. Eliasson L, Clifford S, Barber N, Marin D (2011) Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35:626-630
8. Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, Nandennavar M (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86:471-474
9. Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67-74 (Pubitemid 16125389)
10. Kjellgren KI, Ahlner J, Saljo R (1995) Taking antihypertensive medication-controlling or co-operating with patients? Int J Cardiol 47:257-268
11. Kjellgren KI, Ahlner J, Dahlof B, Gill H, Hedner T, Saljo R (1998) Patients' and physicians' assessment of risks associated with hypertension and benefits from treatment. J Cardiovasc Risk 5:161-166 (Pubitemid 28526887)
12. Sodergard B, Halvarsson M, Tully MP, Mindouri S, Nordstrom ML, Lindback S, Sonnerborg A, Lindblad AK (2006) Adherence to treatment in Swedish HIV-infected patients. J Clin Pharm Ther 31:605-616 (Pubitemid 44813773)
13. Sodergard B, Halvarsson M, Lindback S, Sonnerborg A, Tully MP, Lindblad AK (2006) Differences in adherence and motivation to HIV therapy-two independent assessments in 1998 and 2002. Pharm World Sci 28:248-256 (Pubitemid 44673753)
14. Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10:348-354
15. Bland JM, Altman DG (1997) Cronbach's alpha. BMJ 314:572 (Pubitemid 27089377)
16. Svenska KML-gruppen (2010) Nationella riktlinjer för diagnostik och behandling av kronisk myeloisk leukemi. www.sfhem.se
17. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041-6051
18. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037 (Pubitemid 32267972)
19. Beillard E, Pallisgaard N, van dVV, Bi W, Dee R, der SE Van, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 17:2474-2486 (Pubitemid 38072587)
20. Gabert J, Beillard E, van dVV, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De MD, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ (2003) Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 17:2318-2357 (Pubitemid 38072573)
21. Krousel-Wood M, Hyre A, Muntner P, Morisky D (2005) Methods to improve medication adherence in patients with hypertension: current status and future directions. Curr Opin Cardiol 20:296-300 (Pubitemid 40896368)
22. Shalansky SJ, Levy AR, Ignaszewski AP (2004) Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother 38:1363-1368 (Pubitemid 39100185)
23. Krousel-Wood M, Thomas S, Muntner P, Morisky D (2004) Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 19:357-362 (Pubitemid 38916494)
24. Elm JJ, Kamp C, Tilley BC, Guimaraes P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S (2007) Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord 22:822-827 (Pubitemid 46800103)
25. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P (2009) New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 15:59-66
26. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377:127-138